Vetdrugs 2.0Sarolaner is an isoxazoline ectoparasiticide used for flea and tick control in dogs. It also has clinical activity against selected mites, including Demodex and Sarcoptes species. Combination products pair it with other antiparasitics for a broader spectrum; those companion ingredients provide the additional heartworm or intestinal-worm activity.
Group
Isoxazoline ectoparasiticide
Mechanism of Action
Sarolaner inhibits arthropod ligand-gated chloride channels, particularly GABA-gated and glutamate-gated channels. Reduced inhibitory signaling produces uncontrolled neural excitation, paralysis and parasite death. Systemic exposure allows susceptible blood-feeding parasites to encounter active drug during feeding. Formulation and exposure determine the duration of activity against the targeted ectoparasites.
Dose Rates
Dogs
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Demodex infection | 2–4 mg/kg | PO | Every 720 h | Do not use in: Dogs younger than 6 months, Cats; Reported once-monthly use follows the same whole-tablet presentation and weight bands. Minimum sarolaner exposure is 2 mg/kg; use the verified band, not fractional-chew arithmetic. |
| Flea and tick control | 2–4 mg/kg | PO | Every 720 h | Do not use in: Dogs younger than 6 months, Cats; Once monthly; the exact whole-tablet band controls tablet count. Exposure endpoints are approximate label ranges. |
Indications
- Treatment and prevention of flea infestations in dogs.
- Treatment and control of susceptible tick infestations in dogs according to the product’s parasite spectrum.
- Treatment of selected canine demodicosis or sarcoptic mange with a corresponding product or supported regimen.
- Treatment of selected canine ear-mite infestations, according to local authorization or a supported extra-label regimen.
Contraindications
- Use caution with seizure history; reproductive safety is unestablished.
- Single-agent product is for dogs; safe feline dosing is unestablished.
Adverse effects
- Vomiting, diarrhea, lethargy, tremor and seizures.
Preparations
| Preparation | Form | Strength | Route |
|---|---|---|---|
| Simparica 5 mg chewable tablet Give the whole tablet matching the weight band; ensure complete consumption. Do not substitute a combination chew. Whole tablets only; dog 1.27005864–2.49475804 kg: 1 tablet. | Tablet | 5 mg / tablet | PO |
| Simparica 10 mg chewable tablet Give the whole tablet matching the weight band; ensure complete consumption. Do not substitute a combination chew. Whole tablets only; dog 2.54011727–4.98951607 kg: 1 tablet. | Tablet | 10 mg / tablet | PO |
| Simparica 20 mg chewable tablet Give the whole tablet matching the weight band; ensure complete consumption. Do not substitute a combination chew. Whole tablets only; dog 5.03487531–9.97903214 kg: 1 tablet. | Tablet | 20 mg / tablet | PO |
| Simparica 40 mg chewable tablet Give the whole tablet matching the weight band; ensure complete consumption. Do not substitute a combination chew. Whole tablets only; dog 10.02439138–19.95806428 kg: 1 tablet. | Tablet | 40 mg / tablet | PO |
| Simparica 80 mg chewable tablet Give the whole tablet matching the weight band; ensure complete consumption. Do not substitute a combination chew. Whole tablets only; dog 20.00342352–39.91612856 kg: 1 tablet. | Tablet | 80 mg / tablet | PO |
| Simparica 120 mg chewable tablet Give the whole tablet matching the weight band; ensure complete consumption. Do not substitute a combination chew. Whole tablets only; dog 39.9614878–59.87419284 kg: 1 tablet. | Tablet | 120 mg / tablet | PO |
Monitoring and Administration
Use the exact single-agent chew strength and its verified weight band. Single-agent sarolaner and combination sarolaner/moxidectin/pyrantel products have different dose bases.
Store below 30 C in original packaging.